Controlled Release Levodopa/Carbidopa 25/100 (Sinemet CR 25/100)Pharmacokinetics and Clinical Efficacy in Untreated Parkinsonian Patients
作者:
John Hammerstad,
William Woodward,
John Nutt,
Stephen Gancher,
Gilbert Block,
George Cyhan,
期刊:
Clinical Neuropharmacology
(OVID Available online 1994)
卷期:
Volume 17,
issue 5
页码: 429-434
ISSN:0362-5664
年代: 1994
出版商: OVID
关键词: Controlled release levodopa/carbidopa (Sinemet CR) 25/100;Pharmacokinetics;Levodopa;Parkinson's disease
数据来源: OVID
摘要:
SummaryThe pharmacokinetics of the clinically determined optimal dose of controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100) after 12 weeks of therapy was studied in nine parkinsonian patients without prior exposure to levodopa. The pharmacokinetics of single oral doses of controlled release levodopa/carbidopa 25/100 and 50/200 were also compared. As predicted from the plasma half-life (1.7 ± 0.3 h) and confirmed by morning trough levels, levodopa did not accumulate when controlled released levodopa/carbidopa 25/100 was administered twice daily. The absorption and bioavailability of CR 25/100 are minimally greater than CR 50/200. Controlled released levodopa/carbidopa 25/100 levodopa plasma levels peak slightly faster than controlled release levodopa/carbidopa 50/200.
点击下载:
PDF
(318KB)
返 回